TY - JOUR
KW - Treatment
KW - Multidrug therapy
KW - leprosy
KW - Full text online
KW - Dapsone
AU - Deps P
AU - Guerra P
AU - Nasser S
AU - Simon M
AB - Introduction: Multidrug therapy for leprosy is currently done with dapsone, clofazimine and rifampicin. Dapsone is known to cause hemolytic anemia (HA) and this adverse event duringMDTseems to be more frequent than reported. The aim of this report is to discuss and grade HA due to dapsone during MDT treatment for leprosy.
Methods: This is a retrospective study of 194 leprosy patients from a Leprosy Control Programme Unit in Vito´ria-ES, Brazil.
Results: HA was observed in 48 (24·7%) patients and occurred within the first 3 months in 51% of these. Mean hematocrit levels fell from 38·5 to 31·5 and
hemoglobin from 12·8 to 10·3.
Conclusion: Dapsone used in theMDT regime for leprosy decreases the hematocrit and hemoglobin levels due to a low grade hemolysis, which can result in significant anemia.
BT - Leprosy review
C1 - http://www.ncbi.nlm.nih.gov/pubmed/23356031
CN - DEPS 2012
DA - 10.2012
J2 - Lepr Rev
LA - eng
N2 - Introduction: Multidrug therapy for leprosy is currently done with dapsone, clofazimine and rifampicin. Dapsone is known to cause hemolytic anemia (HA) and this adverse event duringMDTseems to be more frequent than reported. The aim of this report is to discuss and grade HA due to dapsone during MDT treatment for leprosy.
Methods: This is a retrospective study of 194 leprosy patients from a Leprosy Control Programme Unit in Vito´ria-ES, Brazil.
Results: HA was observed in 48 (24·7%) patients and occurred within the first 3 months in 51% of these. Mean hematocrit levels fell from 38·5 to 31·5 and
hemoglobin from 12·8 to 10·3.
Conclusion: Dapsone used in theMDT regime for leprosy decreases the hematocrit and hemoglobin levels due to a low grade hemolysis, which can result in significant anemia.
PY - 2012
SP - 305
EP - 307
T2 - Leprosy review
TI - Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy
UR - https://leprosyreview.org/article/83/3/00-305
VL - 83
ER -